Pharmacology of epidermal growth factor inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Malignant diseases are increasingly understood at the molecular level, identifying specific targets for novel therapeutic agents.
• The epidermal growth factor receptor (EGFR) is a validated target in human cancer due to its role in tumor progression.
• EGFR inhibitors represent a significant advancement in cancer chemotherapy.

Purpose of the Study:

• To review the development and clinical application of agents targeting the epidermal growth factor receptor (EGFR).
• To discuss the mechanisms of action and therapeutic effects of EGFR inhibitors.
• To explore emerging strategies for enhancing EGFR inhibition efficacy and overcoming resistance.

Main Methods:

• Review of current literature on EGFR inhibitors in cancer therapy.
• Analysis of the molecular mechanisms underlying EGFR signaling and inhibition.
• Examination of clinical data for approved and investigational anti-EGFR agents.

Main Results:

• Two main classes of EGFR inhibitors are in clinical use: monoclonal antibodies and small-molecule tyrosine kinase inhibitors.
• These agents interfere with critical cancer cell functions, including cell cycle progression, apoptosis, angiogenesis, and metastasis.
• Approved drugs like cetuximab, gefitinib, and erlotinib demonstrate clinical efficacy in treating specific cancers.

Conclusions:

• EGFR inhibitors are established therapeutic options for cancer treatment.
• Ongoing research focuses on developing new agents and combinatorial approaches to improve treatment outcomes.
• Strategies aim to enhance potency, pharmacokinetics, synergistic activity with chemotherapy, and overcome resistance mechanisms.